Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bayer AG is currently conducting a study titled ‘FINE-REAL: A Non-interventional Study Providing Insights Into the Use of Finerenone in a Routine Clinical Setting.’ The study aims to gather real-world data on the use of Finerenone, a drug prescribed for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This research is significant as it seeks to understand treatment patterns and outcomes in a real-world setting, offering valuable insights into the drug’s effectiveness and safety.
The intervention being tested is the drug Kerendia, also known as Finerenone (BAY94-8862). It is designed to block mineralocorticoid receptors, which are believed to contribute to kidney and heart damage. The drug is already approved for use in patients with CKD and T2D, but this study aims to provide further information on its application in everyday medical practice.
This observational study follows a cohort model with a prospective time perspective. Participants are individuals newly prescribed Finerenone as part of their routine treatment. The study will collect data on various clinical characteristics, treatment patterns, and any adverse events experienced by the participants.
The study began on June 13, 2022, with an estimated completion date set for September 2027. The most recent update was submitted on August 5, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential findings that could impact clinical practice and market dynamics.
From a market perspective, this study could influence Bayer’s stock performance and investor sentiment, particularly if the findings support the efficacy and safety of Finerenone. The drug’s success in the real-world setting could enhance Bayer’s competitive position in the pharmaceutical market, especially against other companies offering treatments for CKD and T2D.
The FINE-REAL study is ongoing, with further details available on the ClinicalTrials portal.